Paid Clinical Trials in Boston, MA

As of August 2026, 2,876 paid clinical trials are recruiting in Boston, Massachusetts. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 10, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

2,490 clinical trials

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

for Non-small Cell Lung Cancer

Drug: Zongertinib

Sites in Boston +27 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07195695·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

for Symptomatic Venous Thromboembolism (VTE)

Sites in Boston +26 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07213778·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

Drug: Pasritamig

Sites in Boston +50 more locations

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

for Hidradenitis Suppurativa (HS)

Drug: Povorcitinib

Sites in Boston +25 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 12 - 17

Code: NCT07213973·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

for Respiratory Syncytial Virus Infections

Sites in Boston +34 more locations

Sponsor: Shionogi

Sex: All·Age: 18+

Code: NCT07214571·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

for Atrial Fibrillation (AF)

Sites in Boston +40 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07175428·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

for Renal Cell Carcinoma (RCC)

Sites in Boston +43 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

for Parkinson's Disease

Drug: Prasinezumab

Sites in Boston +49 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 85

Code: NCT07174310·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

for Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Survodutide

Sites in Boston +162 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632444·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

Sites in Boston +127 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

for Proteinuric Kidney Disease

Sites in Boston, Roxbury +164 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 10 - 65

Code: NCT05312879·Phase 2, Phase 3·Recruiting·Listed Apr 2022

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

Sites in Boston, Foxborough +122 more locations

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

Sites in Boston, Newton +167 more locations

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for End Stage Kidney Disease

Drug: Clazakizumab

Sites in Boston +146 more locations

Sponsor: CSL Behring

Sex: All·Age: 18+

Code: NCT05485961·Phase 2, Phase 3·Recruiting·Listed Aug 2022

Apply to this trial

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

for Age-related Macular Degeneration (AMD)

Drug: Cemdisiran

Sites in Boston, Worcester +138 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 50 - 85

Code: NCT06541704·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

for Multiple Myeloma

Drug: Elranatamab

Sites in Boston +92 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06152575·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

for Diabetes Mellitus, Type 1

Sites in Boston +43 more locations

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT07076199·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for Advanced Non-Small Cell Lung Cancer

Drug: Adagrasib

Sites in Boston, Brighton +190 more locations

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT04613596·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

Drug: Durvalumab

Sites in Boston +49 more locations

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

for Crohn's Disease

Drug: Tulisokibart

Sites in Boston +70 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 16 - 80

Code: NCT06430801·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Drug: Giredestrant

Sites in Boston +46 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

Drug: Polatuzumab Vedotin

Sites in Boston +70 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

Drug: Ribociclib

Sites in Boston, Milford +83 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Assessment of CCM in HF With Higher Ejection Fraction

for Heart Failure

Sites in Boston +75 more locations

Sponsor: Impulse Dynamics

Sex: All·Age: 18+

Code: NCT05064709·Recruiting·Listed Oct 2021

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

Sites in Boston +51 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in Boston, Burlington +86 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

for Breast Cancer

Sites in Boston +48 more locations

Sponsor: Greenwich LifeSciences, Inc.

Sex: All·Age: 18 - 100

Code: NCT05232916·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

Drug: sigvotatug vedotin

Sites in Boston, Newton +102 more locations

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

for Chronic Kidney Disease

Drug: Empagliflozin

Sites in Boston +29 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 2 - 17

Code: NCT07107945·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

for COVID-19 SARS-CoV-2 Infection

Sites in Boston, Worcester +82 more locations

Sponsor: Pfizer

Sex: All·Age: 12+

Code: NCT06679140·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

Sites in Boston, North Worcester +76 more locations

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

Drug: Glofitamab

Sites in Boston +32 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

for COVID-19 Infection

Sites in Boston, Worcester +65 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07013474·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

Sites in Boston +60 more locations

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

Sites in Boston +45 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06973187·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

for Diabetic Peripheral Neuropathic Pain

Sites in Boston, Waltham +57 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 18 - 80

Code: NCT06628908·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

for Chronic Spontaneous Urticaria (CSU)

Drug: Remibrutinib

Sites in Boston +127 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06868212·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for Endometrial Cancer

Sites in Boston +45 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06952504·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

for Alzheimer Disease

Sites in Boston, Watertown +38 more locations

Sponsor: Lighthouse Pharmaceuticals, Inc.

Sex: All·Age: 55 - 80

Code: NCT06847321·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

for Diabetes Mellitus, Type 2

Sites in Boston +122 more locations

Sponsor: Cleerly, Inc.

Sex: All·Age: 55+·Accepts healthy volunteers

Code: NCT06112418·Recruiting·Listed Nov 2023

Apply to this trial